Chronic obstructive pulmonary disease (COPD) is a lung condition that often hides in plain sight. You may think you're ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Researchers have found in two longitudinal cohorts that Incorporating chest CT imaging and respiratory symptoms into the ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Many individuals with chronic obstructive pulmonary disease describe exacerbations in personal, varied terms, revealing a ...

Merck to acquire respiratory drug maker, Verona Pharma for $10 billion: Rahway, New Jersey Thursday, July 10, 2025, 09:00 Hrs [IST] Merck, known as MSD outside of the United State ...